Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity.
A case is reported of reversible sensorineural hearing loss associated with intravenous erythromycin treatment. Cis-platinum induced high frequency hearing loss developed nine months previously during treatment for stage IV papillary cystadenocarcinoma. Renal and hepatic function were normal; however, serum erythromycin levels were elevated. Clinical recovery promptly followed discontinuation of erythromycin.
Wallach
P M
PM
Department of Internal Medicine, University of South Florida College of Medicine, Tampa.
Love
S R
SR
Fiorica
J V
JV
Hoffman
M S
MS
Flannery
M T
MT
D002945:Cisplatin / Q000009:adverse effects*; D003536:Cystadenocarcinoma / Q000188:drug therapy; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D005260:Female; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced*; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced*; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy
D004917:Erythromycin; D002945:Cisplatin